Maysa Abu-Khalaf ABRCC-4

    Clinical Researchers Showcase Series - September 2018

    Translational Medicine Research:

 View from the Trenches Newsletter


Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted only
in a lab, to bedside clinical practice or dissemination to population-based community interventions. (Source: NIH)

from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Maysa Abu-Khalaf, MD

Thomas Jefferson University, Philadelphia, PA

ABRCC Investigator

Maysa Abu-Khalaf, MD is Associate Professor of Medicine at Thomas Jefferson University as well as Director, Breast Medical Oncology Program and Co-Director, Breast Care Center.


Dr. Abu-Khalaf graduated from the University of Jordan, Fac of Med, Amman, Jordan in 1995 and specializes in Medical Oncology.  She did her Fellowship at Yale-New Haven Hospital in New Haven, CT, her Residency at Jordan University Hospital and Internship at Norwalk Hospital, Norwalk CT.  She is Board Certified in Medical Oncology.


See Dr Abu-Khalaf on YouTube


She serves on multiple professional, academic and scientific committees, including the Dept of Defense, SWOG, and protocol reviews.  She maintains both teaching and clinical responsibilities, while also serving on editorial review boards for various cancer/oncology journals including the Cancer Journal and The Oncologist.  She lectures extensively in the US and internationally.


 Recent Trial on ClinicalTrials.Gov


About Jefferson/Abington & Kimmel Cancer Center
Jefferson University Hospitals and Thomas Jefferson University are partners in providing excellent clinical and compassionate care for our patients in the Philadelphia region, educating the health professionals of tomorrow in a variety of disciplines and discovering new knowledge that will define the future of clinical care. Jefferson has topped the list of hospitals in Pennsylvania (3rd) and the Philadelphia metro area (2nd) in U.S.News & World Report's annual listing of the best hospitals and specialties. Learn more at:


for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.


To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.

The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website